 LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, United Kingdom , Nov. 18, 2019 CNW Telbec - Liminal BioSciences Inc. NASDAQ: LMNL TSX: LMNL Liminal BioSciences or the Company, a clinical-stage biotechnology company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that its registration statement on Form F-10 the Registration Statement, which was filed with the United States Securities and Exchange Commission the SEC on November 12, 2019 under the Canada-U.S. multijurisdictional disclosure system, was declared effective on November 15, 2019 . The registration statement contains the previously filed final short form base shelf prospectus dated March 14, 2018 the Shelf Prospectus, which was prepared in accordance with the shelf prospectus regulations under Canadian securities legislation and has now been filed under the Canada-U.S. multijurisdictional disclosure system as part of the Registration Statement. 